Letrozole

Common brands: Femara, Ibrance, Kisqali, Xgeva, Faslodex

Top reporter: Novartis Pharmaceuticals Corporation

Aromatase Inhibitor [EPC]Kinase Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]RANK Ligand Inhibitor [EPC]Estrogen Receptor Antagonist [EPC]
60,074
Total Reports
28,867
Serious Reports
5,933
Death Reports
30
Reported Reactions
Death Report Ratio: High (9.88%)

Patient Demographics

Male
854
Female
55,266

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Letrozole.

# Reaction Reports % of Total
1 FATIGUE 7,285
8.3%
2 NAUSEA 5,365
6.1%
3 NEUTROPENIA 5,007
5.7%
4 DIARRHOEA 4,571
5.2%
5 MALIGNANT NEOPLASM PROGRESSION 4,379
5.0%
6 ARTHRALGIA 3,881
4.4%
7 WHITE BLOOD CELL COUNT DECREASED 3,740
4.3%
8 ALOPECIA 3,629
4.2%
9 PAIN 2,993
3.4%
10 ASTHENIA 2,920
3.3%
11 DYSPNOEA 2,888
3.3%
12 NEOPLASM PROGRESSION 2,795
3.2%
13 VOMITING 2,727
3.1%
14 DEATH 2,634
3.0%
15 HEADACHE 2,433
2.8%
16 DECREASED APPETITE 2,347
2.7%
17 METASTASES TO BONE 2,311
2.6%
18 ANAEMIA 2,214
2.5%
19 DIZZINESS 2,211
2.5%
20 MALAISE 2,154
2.5%
21 OFF LABEL USE 2,137
2.4%
22 PYREXIA 1,991
2.3%
23 DISEASE PROGRESSION 1,969
2.3%
24 BREAST CANCER METASTATIC 1,968
2.3%
25 COUGH 1,945
2.2%
26 BREAST CANCER 1,823
2.1%
27 PAIN IN EXTREMITY 1,771
2.0%
28 DRUG INEFFECTIVE 1,755
2.0%
29 BACK PAIN 1,737
2.0%
30 CONSTIPATION 1,666
1.9%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.